地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18327026838
传真：17754422825
邮箱：sales@amyjet.com
<艾美捷科技代理Clearsynth品牌全系列产品
Clearsynth研发中心位于海得拉巴，以“创新与精准之心”为核心理念，打造了一个精心设计的空间，旨在激发突破性的发现并提升可能性的界限。专注于创新有机化学和独特复杂分子的合成，涵盖稳定同位素标记化合物、代谢物、杂质、葡萄糖醛酸、手性化合物、共轭物杂质和放射性标记化合物等。承接复杂分子或“难以合成”的合成化合物/中间体的定制合成服务。提供超过3,59,000个高纯度参考标准品，Clearsynth公司的产品线包括稳定同位素、原料药、杂质、亚硝胺、二级标准、散装化合物等。
▍Clearsynth服务领域
● 小分子：合成各种精细化学品和化合物，用于从毫克到数公斤规模的小分子药物发现。
● 工艺开发：开发新的合成路线，也可以修改和优化客户提供的工艺。
● 合同研发综合：专注于从临床前阶段到III期以及成功的技术转让。
● 生物核磁共振服务：位于海得拉巴的符合GLP标准的高场生物核磁共振/600MHz和300MHz设施，由敬业且经验丰富的核磁共振操作员提供支持。
● CDMO服务：致力于复杂、危险和可持续的产品和工艺。
● 分析服务：符合FDA、BIS、卫生部和其他标准机构制定的所有监管规范。
▍Clearsynth部分产品列表
| 品名 | 货号 | CAS号 |
| α-Keto Isovaleric Acid Sodium Salt 13C D6 | CS-R-00562 | 3715-29-5 (Unlabeled) |
| α-Keto Isovaleric Acid Sodium Salt 13C5 | CS-R-00482 | 1173018-24-0 |
| α-Keto Isovaleric Acid Sodium Salt D6 | CS-R-00485 | 3715-29-5(Unlabeled) |
| α-Keto Isovaleric Acid Sodium Salt Dimethyl-13C2 | CS-R-00488 | 634908-42-2 |
| α-KETOBUTYRIC ACID, SODIUM 13C, D4 | CS-R-00475 | 2013-26-5 (Unlabeled) |
| α-KETOBUTYRIC ACID, SODIUM SALT 13C4, D2 | CS-R-00477 | 360769-17-1 |
| α-KETOBUTYRIC ACID, SODIUM SALT METHYL-13C | CS-R-00478 | 634908-43-3 |
| α-KETOBUTYRIC ACID, SODIUM SALT METHYL-13C, D2 | CS-R-00479 | 1007476-77-8 |
| α-Ketobutyric Acid-d2 Sodium Salt | CS-T-30294 | 1007476-82-5 |
| α-Ketoglutaric acid 13C2, D2 | CS-CX-00331 | 123953-28-6 |
| α-KETOGLUTARIC ACID 13C5 | CS-R-00549 | 161096-83-9 |
| α-KETOGLUTARIC ACID, DISODIUM SALT 13C4 | CS-R-00480 | 1429051-79-5 |
| α-KETOISOCAPROIC ACID 13C | CS-R-00551 | 92751-19-4 |
| α-KETOISOCAPROIC ACID, SODIUM SALT 13C2 | CS-R-00552 | 4502-00-5(Unlabeled) |
| α-KETOISOCAPROIC ACID, SODIUM SALT ISOPROPYL-D7 | CS-R-00555 | 1795020-84-6 |
| α-Tocopherol-[13C3] | CS-I-00340 | 59-02-9 (Unlabeled) |
| β-ALANINE 13C | CS-R-00042 | 65138-34-3 |
| β-ALANINE 13C, 15N | CS-R-00449 | 1822942-84-6 |
| β-ALANINE 13C3 | CS-R-00040 | 107-95-9 (Unlabeled) |
| β-ALANINE 15N | CS-R-00041 | 204451-53-6 |
| β-CAROTENE 13C4 | CS-R-00567 | 7235-40-7(Unlabeled) |
| -β-Cyclocitral-d5 | CS-T-51410 | 78995-98-9 |
| β-Endosulfan D4 | CS-O-15034 | 203716-99-8 |
| β-Ionone-[13C3] | CS-I-00368 | 14901-07-6 (Unlabeled) |
| βmethasone 17-propionate-d3 | CS-O-10426 | 5534-13-4 (Unlabeled) |
| β-Tocopherol-[13C9] | CS-I-00341 | 59-02-9 (Unlabeled) |
| γ-HCH D6 | CS-EJ-0009 | 60556-82-3 |
| (-)-(2S,3S)-Viridifloric Acid Acetonide-d7 | CS-T-102816 | 95462-09-2(Unlabelled) |
| (-)-(2S,3S)-Viridifloric Acid Ethyl Ester-d7 | CS-T-102815 | 176712-53-1(Unlabelled) |
| (-)-(3S)-3-Hydroxy Quinine-vinyl-d3 | CS-T-101262 | 2734920-65-9 |
| (-)-(S)-Cibenzoline-D4 | CS-O-33254 | 103419-18-7 (Unlabeled) |
| (-)-2-Amino-6-propionamido-d3-tetrahydrobenzothiazole | CS-T-97805 | 1217644-20-6 |
| (-)-2-Methyl Isoborneol-d3 | CS-T-58298 | 135441-89-3 |
| (-)-alfa-Benidipine-d5 Hydrochloride | CS-P-07295 | 129262-07-3 (Unlabeled) |
| (-)-Cannabidiol-d9 | CS-TA-86322 | 1246819-21-5 |
| (-)-Citrinin-13C,d2 | CS-T-72877 | 1329611-85-9 |
Mirus Bio公司是世界上最早开发高效、低细胞毒性转染试剂的公司之一，同时也是目前该类试剂最主要的供应商之一。Mirus Bio的大部分转染试剂可以在含有血清的培养基中进行转染，省去了更换培养基的麻烦。TransIT-L1是Mirus产品的王牌，自1995年开发出来就申请了美国专利(US 5,744,335)。该项专利技术后来License给了Roche公司，以Fugene 6的品牌对外销售。TransIT-TKO & siQUEST转染试剂是常规siRNA转染试剂的王牌，与脂质体介导的转染试剂相比，该转染试剂可以高效转染siRNA，并且极大地降低了细胞的损伤程度。该试剂与siRNA混合转染细胞时，可以特异性剔除某些基因的表达，用于siRNA介导的基因沉默现象的研究。TransIT-Oligo转染试剂是即用型试剂，可以高效地将各种类型的寡聚核苷酸和寡聚脱氧核苷酸转染至受体细胞中。
此外，Mirus Bio还开发了专门针对特殊细胞的体外转染试剂，例如分别针对Jurkat，COS，3T3等细胞的转染试剂。Mirus Bio的科学家们新近开发了一种新的DNA转染试剂：TransITTM-2020 Transfection Reagent。TransITTM的性能优于FuGENETM、LipofectamineTM 2000和 LipofectamineTM 2000 CD；可在多种类型的细胞（包括难转染细胞）中实现高表达。
Mirus was founded on the principle that non-viral (i.e. plasmid DNA based) methods offer distinct advantages over viral methods of gene transfer. Our initial breakthrough in 1996 came with the development of a new type of transfection reagent that combined high efficiency delivery with low cellular toxicity: TransIT®-LT1 (Low Toxicity) Reagent remains the “gold standard” for broad-based gene delivery applications.
Mirus Bio公司主要产品：
Transfection with TransIT
Ingenio® Electroporation
Virus Production
Labeling with Label IT®
In Vivo Delivery
Accessory Products
| 品名 | 货号 |
| Human IgG1 Expression Control – 100 ug | MIR 6250 |
| Ingenio EZporator Electroporation System | MIR 51000 |
| Label IT Nucleic Acid Labeling Kit, Amine – sufficient for modifying 25 µg of nucleic acid | MIR 3925 |
| Label IT Nucleic Acid Labeling Kit, Amine – sufficient for modifying 100 µg of nucleic acid | MIR 3900 |
| TransIT-2020 Transfection Reagent – 0.4 mL | MIR 5404 |
| TransIT-2020 Transfection Reagent – 1.0 mL | MIR 5400 |
| TransIT-2020 Transfection Reagent – 10 X 1.0 mL | MIR 5406 |
| TransIT-2020 Transfection Reagent – 5 X 1.0 mL | MIR 5405 |
| TransIT-293 Transfection Reagent – 0.4 mL | MIR 2704 |
| TransIT-293 Transfection Reagent – 1.0 mL | MIR 2700 |
| TransIT-293 Transfection Reagent – 10 X 1.0 mL | MIR 2706 |
| TransIT-293 Transfection Reagent – 5 X 1.0 mL | MIR 2705 |
| TransIT-CHO Transfection Kit – 10 X 1.0 mL | MIR 2176 |
| TransIT-CHO Transfection Kit – 5 X 1.0 mL | MIR 2175 |
| TransIT-CHO Transfection Kit – 1.0 mL | MIR 2170 |
| TransIT-HeLaMONSTER Transfection Kit – 0.4 mL | MIR 2904 |
| TransIT-HeLaMONSTER Transfection Kit – 1.0 mL | MIR 2900 |
| TransIT-HeLaMONSTER Transfection Kit – 10 X 1.0 mL | MIR 2906 |
| TransIT-HeLaMONSTER Transfection Kit – 5 X 1.0 mL | MIR 2905 |
| TransIT-Insect Transfection Reagent – 0.4 mL | MIR 6104 |
| TransIT-Insect Transfection Reagent – 1.0 mL | MIR 6100 |
| TransIT-Insect Transfection Reagent – 10 X 1.0 mL | MIR 6106 |
| TransIT-Insect Transfection Reagent – 5 X 1.0 mL | MIR 6105 |
| TransIT-Jurkat Transfection Reagent – 0.4 mL | MIR 2124 |
| TransIT-Jurkat Transfection Reagent – 1.0 mL | MIR 2120 |
| TransIT-Jurkat Transfection Reagent – 10 X 1.0 mL | MIR 2126 |
| TransIT-Jurkat Transfection Reagent – 5 X 1.0 mL | MIR 2125 |
| TransIT-Keratinocyte Transfection Reagent – 0.4 mL | MIR 2804 |
| TransIT-Keratinocyte Transfection Reagent – 1.0 mL | MIR 2800 |
| TransIT-Keratinocyte Transfection Reagent – 10 X 1.0 mL | MIR 2806 |
| TransIT-Keratinocyte Transfection Reagent – 5 X 1.0 mL | MIR 2805 |
| TransIT-LT1 Transfection Reagent – 0.4 mL | MIR 2304 |
| TransIT-LT1 Transfection Reagent – 5 X 1.0 mL | MIR 2305 |
| TransIT-mRNA Transfection Kit – 0.4 mL | MIR 2225 |
| TransIT-mRNA Transfection Kit – 1.0 mL | MIR 2250 |
| TransIT-mRNA Transfection Kit – 10 X 1.0 mL | MIR 2256 |
| TransIT-mRNA Transfection Kit – 5 X 1.0 mL | MIR 2255 |
| TransIT-Oligo Transfection Reagent – 0.4 mL | MIR 2164 |
| TransIT-Oligo Transfection Reagent – 1.0 mL | MIR 2160 |
| TransIT-Oligo Transfection Reagent – 10 X 1.0 mL | MIR 2166 |
| TransIT-Oligo Transfection Reagent – 5 X 1.0 mL | MIR 2165 |
| TransIT-PRO Transfection Kit – 1.0 mL (with boost) | MIR 5700 |
| TransIT-PRO Transfection Kit – 10 mL (with boost) | MIR 5760 |
| TransIT-PRO Transfection Reagent – 1 mL (without boost) | MIR 5740 |
| TransIT-PRO Transfection Reagent – 10 mL (without boost) | MIR 5750 |
| TransIT-siQUEST Transfection Reagent – 0.4 mL | MIR 2114 |
| TransIT-siQUEST Transfection Reagent – 1.5 mL | MIR 2110 |
| TransIT-siQUEST Transfection Reagent – 10 X 1.5 mL | MIR 2116 |
| TransIT-siQUEST Transfection Reagent – 5 X 1.5 mL | MIR 2115 |
| TransIT-TKO Transfection Reagent – 0.4 mL | MIR 2154 |
| TransIT-TKO Transfection Reagent – 1.5 mL | MIR 2150 |
| TransIT-TKO Transfection Reagent – 10 X 1.5 mL | MIR 2156 |
| TransIT-TKO Transfection Reagent – 5 X 1.5 mL | MIR 2155 |
| TransIT-X2 Dynamic Delivery System – 0.3 mL | MIR 6003 |
| TransIT-X2 Dynamic Delivery System – 0.75 mL | MIR 6004 |
| TransIT-X2 Dynamic Delivery System – 1.5mL | MIR 6000 |
| TransIT-X2 Dynamic Delivery System – 10 X 1.5 mL | MIR 6006 |
| TransIT-X2 Dynamic Delivery System – 5 X 1.5 mL | MIR 6005 |
| Ingenio Electroporation Accessory – Cell Droppers (50 pk) | MIR 50125 |
| Ingenio Electroporation Solution Only – 25 rxns (6.25 mL) | MIR 50111 |
| Label IT Nucleic Acid Labeling Kit, Biotin – labels 100 µg nucleic acid | MIR 3400 |
| Label IT Plasmid Delivery Control, Cy3 – 10 µg | MIR 7904 |
| Label IT RNAi Delivery Control, Cy3 – 10 µg (0.75 nmol) | MIR 7900 |
| TransduceIT Transduction Reagent – 1 mL | MIR 6620 |
| TransIT-BrCa Reagent Transfection Reagent – 0.4 mL | MIR 5504 |
| Ingenio Electroporation Accessory – 0.4 cm Cuvettes (50 pk) | MIR 50123 |
| Ingenio Electroporation Solution Only – 50 rxns (12.5 mL) | MIR 50114 |
| Label IT Nucleic Acid Labeling Kit, Biotin – labels 25 µg nucleic acid | MIR 3425 |
| Label IT Plasmid Delivery Control, Cy3 – 100 µg | MIR 7905 |
| Label IT RNAi Delivery Control, Cy3 – 100 µg (7.5 nmol) | MIR 7901 |
| Label IT siRNA Tracker Intracellular Localization Kit, CX-Rhodamine – labels 50 µg siRNA | MIR 7214 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, CX-Rhodamine – labels 50-200 µg plasmid DNA | MIR 7022 |
| Lentivirus Packaging Mix – 34 rxn | MIR 6640 |
| TransIT-BrCa Reagent Transfection Reagent – 1.0 mL | MIR 5500 |
| TransIT-LT1 Transfection Reagent – 1.0 mL | MIR 2300 |
| Ingenio Electroporation Accessory – 0.2 cm Cuvettes (50 pk) | MIR 50121 |
| Ingenio Electroporation Solution Only – 100 rxns (25 mL) | MIR 50117 |
| Label IT Nucleic Acid Labeling Kit, CX-Rhodamine – labels 100 µg nucleic acid | MIR 3100 |
| Label IT Plasmid Delivery Control, Fluorescein – 10 µg | MIR 7906 |
| Label IT RNAi Delivery Control, Fluorescein – 10 µg (0.75 nmol) | MIR 7902 |
| Label IT siRNA Tracker Intracellular Localization Kit, Cy3 – labels 50 µg siRNA | MIR 7212 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, Cy3 – labels 50-200 µg plasmid DNA | MIR 7020 |
| Lentivirus Packaging Mix – 5 rxn | MIR 6630 |
| TransIT-BrCa Transfection Reagent – 5 x 1.0 mL | MIR 5505 |
| Ingenio Electroporation Kit, for Amaxa – 25 rxns (0.2 cm Cuvettes/Droppers) | MIR 50112 |
| Label IT Nucleic Acid Labeling Kit, CX-Rhodamine – labels 25 µg nucleic acid | MIR 3125 |
| Label IT Plasmid Delivery Control, Fluorescein – 100 µg | MIR 7907 |
| Label IT RNAi Delivery Control, Fluorescein – 100 µg (7.5 nmol) | MIR 7903 |
| Label IT siRNA Tracker Intracellular Localization Kit, Cy5 – labels 50 µg siRNA | MIR 7213 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, Cy5 – labels 50-200 µg plasmid DNA | MIR 7021 |
| TransIT Lentivirus System – 34 rxn | MIR 6655 |
| TransIT-BrCa Transfection Reagent – 10 x 1.0 mL | MIR 5506 |
| TransIT-LT1 Transfection Reagent – 10 X 1.0 mL | MIR 2306 |
| Ingenio Electroporation Kit, for Amaxa – 50 rxns (0.2 cm Cuvettes/Droppers) | MIR 50115 |
| Label IT Nucleic Acid Labeling Kit, Cy3 – labels 100 µg nucleic acid | MIR 3600 |
| Label IT siRNA Tracker Intracellular Localization Kit, Fluorescein – labels 50 µg siRNA | MIR 7216 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, Fluorescein – labels 50-200 µg plasmid DNA | MIR 7025 |
| TransIT Lentivirus System – 5 rxn | MIR 6650 |
| Ingenio Electroporation Kit, for Amaxa – 100 rxns (0.2 cm Cuvette/Droppers) | MIR 50118 |
| Label IT Nucleic Acid Labeling Kit, Cy3 – labels 25 µg nucleic acid | MIR 3625 |
| TransIT-Lenti Transfection Reagent – 10 x 1.5 mL | MIR 6606 |
| Ingenio Electroporation Kit, for other Electroporators – 25 rxns, (0.4 cm Cuvettes/Droppers) | MIR 50113 |
| Label IT Nucleic Acid Labeling Kit, Cy5 – labels 100 µg nucleic acid | MIR 3700 |
| TransIT-Lenti Transfection Reagent – 1.5 mL | MIR 6600 |
| Ingenio Electroporation Kit, for other Electroporators – 50 rxns (0.4 cm Cuvettes/Droppers) | MIR 50116 |
| Label IT Nucleic Acid Labeling Kit, Cy5 – labels 25 µg nucleic acid | MIR 3725 |
| TransIT-Lenti Transfection Reagent – 0.75 mL | MIR 6604 |
| Ingenio Electroporation Kit, for other Electroporators – 100 rxns (0.4 cm Cuvette/Droppers) | MIR 50119 |
| TransIT-Lenti Transfection Reagent – 5 x 1.5 mL | MIR 6605 |
| TransIT-Lenti Transfection Reagent – 0.3 mL | MIR 6603 |
| Label IT Nucleic Acid Labeling Kit, DNP – labels 100 µg nucleic acid | MIR 3800 |
| Label IT Nucleic Acid Labeling Kit, DNP – labels 25 µg nucleic acid | MIR 3825 |
| Label IT Nucleic Acid Labeling Kit, Fluorescein – labels 100 µg nucleic acid | MIR 3200 |
| Label IT Nucleic Acid Labeling Kit, Fluorescein – labels 25 µg nucleic acid | MIR 3225 |
| Label IT Nucleic Acid Labeling Kit, MFP488 – labels 100 µg nucleic acid | MIR 7100 |
| Label IT Nucleic Acid Labeling Kit, MFP488 – labels 25 µg nucleic acid | MIR 7125 |
| TransIT-EE Delivery Solution – 40 Injections | MIR 5340 |
| TransIT-QR Delivery Solution – 40 Injections | MIR 5240 |
| pLIVE Vector – 20 ug | MIR 5420 |
| pLIVE Vector/LacZ – 20 ug of each vector | MIR 5520 |
| pLIVE Vector/SEAP Control Vector Kit – 20 ug of each vector | MIR 5620 |
| pLIVE Vector Complete System – 20 ug of each vector | MIR 5320 |
| RevIT AAV Enhancer – 1.5 mL (for 1 L of cell culture) | MIR 8000 |
| TransIT-VirusGEN GMP Transfection Reagent – 150 mL | MIR 6845-GMP |
| VirusGEN AAV Transfection Kit – 150mL | MIR 6755 |
| VirusGEN AAV Transfection Kit, 1 Kit – for 10 L of cell culture | MIR 6745 |
| RevIT AAV Enhancer – 10 x 1.5 mL (for 10 L of cell culture) | MIR 8006 |
| RevIT AAV Enhancer – 75 mL (for 50 L of cell culture) | MIR 8080 |
| VirusGEN GMP LV Transfection Kit | MIR 6825-GMP |
| VirusGEN LV Transfection Kit | MIR 6760 |
| VirusGEN AAV Kit + RevIT for 10L Culture | MIR 8008 |
| VirusGEN GMP AAV Transfection Kit | MIR 6815-GMP |
| VirusGEN AAV Transfection Kit – 1 Kit for 1 L of cell culture | MIR 6750 |
| VirusGEN AAV Kit + RevIT for 1L Culture | MIR 8007 |
| TransIT-VirusGEN Transfection Reagent – 150 mL | MIR 6740 |
| TransIT-VirusGEN Transfection Reagent – 30 mL | MIR 6720 |
| TransIT-VirusGEN Transfection Reagent – 10 x 1.5 mL | MIR 6706 |
| TransIT-VirusGEN Transfection Reagent – 5 x 1.5 mL | MIR 6705 |
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
艾美捷科技特约代理CovaChem公司产品。
CovaChem公司致力于为生命科学领域的科学家提供化学产品。主要涉及的领域是质谱、蛋白质组学、蛋白质科学、药物测试及药物筛选。
CovaChem is a chemical manufacturing company serving research scientists in the life sciences. We are dedicated to producing the highest quality reagents in the marketplace for use in mass spectrometry, proteomics, protein sciences, drug testing and drug development. We offer a wide range of products in both small scale and bulk quantities. For sizes larger than our catalog offering, please contact us for a custom quotation. CovaChem is proud to serve customers around the world, with their chemical, biotech, and analytical product needs. The customer is always our top priority, and this is why we offer an UNCONDITIONAL GUARANTEE for all of our products!
CovaChem的主要产品包括：
Protein Crosslinkers
LCMS & HPLC Mobile Phases
Protein Modifiers
GC Derivatization Reagents
Chemicals
MALDI Matrices
Buffers & Solvents
Beta Glucuronidase
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="CovaChem"> CovaChem
Calbiotech是为世界各地的大学和研究中心定制开发和制造免疫产品的主要参考实验室，产品包括ELISA、超灵敏的化学发光试剂，IVD RIA和PCR试剂盒。
Calbiotech specializes in immunoassay development and manufacturing, with a comprehensive range of ELISA and CLIA assays for human and animal research, including specific assays for hormone, autoimmune disorders, cancer, infectious diseases and much more. The company has over 200 products which are distributed to over 80 countries globally.
Calbiotech is a key partner for biotech, pharma and CROs, providing contract manufacturing and assay development services, including custom coated microplates, reagents, buffers and other assay components.
Calbiotech的主要产品包括：
（1）ELISA KITS
Products For Research
Products For Export
（2）DEVELOPMENT REAGENTS
Coated Plates
Coating & Blocking Buffers
Stabilizers & Substrates
Sample Prep & Assay Optimization
Commons: Wash, Stop, TMB, PBS
（3）CHEMILUMINESCENT
SAV Coated Magnetic Beads
Chemiluminescent Immunoassays
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Calbiotech"> Calbiotech
艾美捷科技代理FormuMax品牌。
FormuMax Scientific公司专注于药物递送领域，基于脂质体和其他新型纳米递送技术，开发了一些列产品。包括：
Mikosome™（外泌体模拟脂质体）
脂质纳米粒子（LNPs）
Clophosome®-氯膦酸脂质体
Doxoves®-脂质体盐酸阿霉素
用于药物装载的脂质体
阳离子脂质体
Trans-Hi™DNA转染试剂
荧光脂质体
预成型脂质体
载药脂质体
特色产品：
聚乙二醇化免疫球蛋白™（生物素化）脂质体，荧光（DiR）标记的Mikosome™（2毫升），荧光（DiO）标记的Mikosome™ (2mL)等等
< " data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理FormuMax品牌"> 艾美捷科技代理FormuMax品牌
艾美捷科技有限公司代理Complement Technology全系列产品。
Complement Technology公司致力于为生物医学研究提供最高质量的补体试剂。Complement Tech的研发人员在补体相关试剂领域拥有80多年的丰富经验，是补体试剂的原始制造商。
Complement Technology公司的主要产品包括：
| Purified Proteins | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| C1 (Pure) | A098 | 0.2 | 200 |
| C1q | A099 | 1 | 1000 |
| C1q (40% Glycerol) | A100 | 1 | 1000 |
| C1r Proenzyme | A101 | 0.5 | 100 |
| C1r Enzyme | A102 | 1 | 250 |
| C1s Proenzyme | A103 | 1 | 250 |
| C1s Enzyme | A104 | 1 | 250 |
| C1 Esterase Inhibitor | A140 | 1 | 1000 |
| C1s-C1INH Complex *(NEW)* | C1040 | 0.5 | 50 |
| C2 | A112 | 0.5 | 50 |
| C3 | A113 | 1 | 250 |
| C3 (concentrated) | A113c | 5 | 1000 |
| C3a | A118 | 0.5 | 50 |
| C3a desArg | A119 | 0.5 | 50 |
| C3b | A114 | 1 | 250 |
| iC3b | A115 | 1 | 250 |
| C3c | A116 | 1 | 250 |
| C3d | A117 | 1 | 100 |
| C4 | A105 | 1 | 250 |
| C4 (concentrated) | A105c | 4 | 1000 |
| C4a | A106 | 0.5 | 50 |
| C4a desArg | A107 | 0.5 | 50 |
| C4b | A108 | 1 | 250 |
| C4b Binding Protein | A109 | 1 | 250 |
| C5 | A120 | 1 | 250 |
| C5a | A144 | 0.5 | 30 |
| C5a (300) | A144(300) | 0.5 | 300 |
| C5a desArg | A145 | 0.5 | 50 |
| C5b,6 | A122 | 0.2 | 50 |
| C6 | A123 | 1 | 250 |
| C7 | A124 | 1 | 250 |
| C8 | A125 | 1 | 250 |
| C9 | A126 | 1 | 250 |
| SC5b-9 Complex | A127 | 1 | 100 |
| Factor B | A135 | 1 | 250 |
| Factor D | A136 | 0.1 | 25 |
| Factor H | A137 | 1 | 250 |
| Factor H (conc.) | A137c | 10 | 10000 |
| Factor I | A138 | 1 | 100 |
| Factor P (Properdin) | A139 | 1 | 100 |
| Cobra Venom Factor (USA Only) | A150 | 1 | 1000 |
| Factor Ba | A154 | 1 | 100 |
| Factor Bb | A155 | 1 | 250 |
| Animal Proteins | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| Cyno C3 (USA Only) | CY113 | 1 | 100 |
| Cyno C3b (USA Only) | CY114 | 1 | 100 |
| Mouse C1q | M099 | 1 | 100 |
| Mouse C3 | M113 | 1 | 100 |
| Mouse C3b | M114 | 1 | 100 |
| Rat C1q | R099 | 1 | 100 |
| See Polyclonal Antisera page for Anti-Mouse C3 | M213 | - | - |
| Anaphylatoxin | |||
| 产品名称 | 货号 | mg/ml | µg/vial |
| C3a | A118 | 0.5 | 50 |
| C3a desArg | A119 | 0.5 | 50 |
| C4a | A106 | 0.5 | 50 |
| C4a desArg | A107 | 0.5 | 50 |
| C5a | A144 | 0.5 | 30 |
| C5a desArg | A145 | 0.5 | 50 |
| C5a (300) | A144(300) | 0.5 | 300 |
| Complement Assay Reagents | |||
| 产品名称 | 货号 | 体积 | |
| GVBo (without Ca and Mg) - 250ml | B103 | 250ml | |
| GVBo (without Ca and Mg) - 1L | B101 | 1 Liter | |
| GVB++ (with Ca and Mg) - 250ml | B102 | 250ml | |
| GVB++ (with Ca and Mg) - 1L | B100 | 1 Liter | |
| GVBE (with EDTA) - 250ml | B104 | 250ml | |
| GVBE (with EDTA) - 1L | B105 | 1 Liter | |
| SGVB++ (low ionic strength w/Sucrose, Ca and Mg) - 250ml | B110 | 250ml | |
| SGVB++(low ionic strength w/Sucrose, Ca and Mg) - 1L | B111 | 1 Liter | |
| VBS++ (with Ca and Mg) - 250ml | B112 | 250ml | |
| VBS++ (with Ca and Mg) - 1L | B113 | 1 Liter | |
| EA (Ab-sensitized sheep E) - 5ml | B200 | 5ml @ 5x10⁸/ml | |
| EA (Ab-sensitized sheep E) - 10ml | B201 | 10ml @ 5x10⁸/ml | |
| EA (Ab-sensitized sheep E) - 20ml | B202 | 20ml @ 5x10⁸/ml | |
| Es (sheep E) | B210 | 20ml @ 5x10⁸/ml | |
| Er (rabbit E) - 5ml | B300 | 5ml @ 5x10⁸ml | |
| Er (rabbit E) - 10ml | B301 | 5ml @ 5x10⁸/ml | |
| Er (rabbit E) - 20ml | B302 | 20ml @ 5x10⁸/ml | |
| Zymosan (preactivated) | B400 | 10ml @ 1x10⁹/ml | |
| MgEGTA | B106 | 10ml @ 0.1M | |
| MCAR | B250 | 1.0 ml | |
| Hemolysin | Hemolysin | 2.0 ml | |
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Complement Technology"> Complement Technology
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年，提供近200种亚磷酰胺和核苷酸合成用固相交联单体，以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.
Berry & Associates的主要产品包括：
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
TOKU-E公司专注于体外抗生素生产技术，并快速成长为世界领先的超纯抗生素供应者，以低廉的价格提供最全面的超纯抗生素，其纯度大于99%，用于动物细胞培养、植物组织培养、微生物、抗真菌及诊断等科研领域，允许研究者提高抗生素浓度，并消除污染，降低对细胞的伤害，从而提高筛选效率；该公司还提供精细化学试剂，如超纯丙烯酰胺、无尘SDS、胍盐等，极大提高了实验的精确性和安全性，可满足生命科学研究领域各科研机构，标准化组织机构的高标准需求。
When our doors first opened in 1981, we were a chemical trading company in Tokyo, Japan called TOKUICHI, which means‘moral first’in Japanese. Having established a firm foundation, our company focused on manufacturing antibiotics through fermentation, then specialized in pharma and biotech research sectors. To reflect our growth into a leading global antibiotic manufacturer, we updated our name to TOKU-E. Though we have expanded our scope to better serve our customers, we still maintain our strong moral fiber.
TOKU-E has facilities in the US, China, Europe, and Singapore to serve you globally, and our network of worldwide distributors offers region-specific expertise. Our company is ISO 9001:2015 certified, for your regulatory peace of mind.
TOKU-E的主要产品包括：
（1）Cell Culture
Gene Selection Antibiotics
Contamination Control
Mycoplasma Detection & Elimination
（2）Cancer Research
Antitumor
Chemotherapeutics
Immunosuppressants
（3）Microbiology
Antimicrobials
Gene Selection Antibiotics
Beta-lactamase Inhibitors
Nitrocefin
Selective Agents
（4）Plant Biology
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="TOKU-E"> TOKU-E
<艾美捷科技代理Synthelis Biotech品牌全系列产品
Synthelis Biotech是一家法国公司，专注于蛋白质的生产、纯化与表征，公司致力于助力疫苗、生物制剂、酶、工程蛋白、诊断工具以及高通量分子或配体筛选技术的开发。Synthelis Biotech提供经过验证的蛋白质，其活性和纯度均根据特定应用（候选药物筛选、抗体与疫苗开发、结构生物学、体外诊断、蛋白质载体化）量身定制。Synthelis Biotech专利的无细胞技术使客户能够从不同蛋白家族（GPCRs、离子通道、转运蛋白等）和不同形式（蛋白脂质体、纳米盘、去垢剂溶解形式或可溶形式）中选择合适的蛋白质。凭借其专利技术，Synthelis 能够在数小时内合成各类蛋白质：包括膜蛋白、毒性蛋白、修饰蛋白等，应用于药物筛选、疫苗与抗体开发、结构生物学以及体外诊断等领域。同时可按需进行修饰（荧光或同位素标记、非天然氨基酸掺入、截短或突变形式等）。
▍Synthelis Biotech产品列表
| 分类 | 品名 | Protein | Origin | Format | Reference | Quantity | 分子量 |
| Viral Proteins | E1 | Envelop protein 1 | Hepatitis C virus | Proteoliposome | PL011 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 21 kDa |
| Viral Proteins | E2 | Envelop protein 1 | Hepatitis C virus | Proteoliposome | PL010 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 21 kDa |
| Viral Proteins | N-protein | Nucleocapsid Protein (COVID-19) | SARS-Cov 2 virus | Soluble | S-144 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 47,7 kDa |
| Viral Proteins | F5L | Vaccinia virus major membrane protein | Vaccinia virus | Proteoliposome | PL007 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 39.0 kDa |
| Viral Proteins | HCV p7 | Hepatitis C virus P7 | HCV virus | Proteoliposome | PL042 | 10µg, 20µg, 50µg, 100µg, 200µg, 500µg | 7 kDa |
| GPCRs | APJ/AR | Apelin Receptor | Human | Proteoliposome | PL061 | 10 µg, 50 µg ,100 µg | 44.7 kDa |
| GPCRs | B2R | Bradykinin receptor 2 | Human | Proteoliposome | PL080 | 10 µg, 50 µg ,100 µg | 47.0 kDa |
| GPCRs | BR | Bacteriorhodopsin | Bacteria | Proteoliposome | PL027 | 10 µg, 50 µg ,100 µg | 29.4 kDa |
| GPCRs | CCR1 | C-C chemokine receptor type 1 | Human | Proteoliposome | PL021 | 10 µg, 50 µg ,100 µg | 43.7 kDa |
| GPCRs | CCR2a | C-C chemokine receptor type 2, isoform a | Human | Proteoliposome | PL022 | 10 µg, 50 µg, 100 µg | 44.5 kDa |
| GPCRs | CCR2b | C-C chemokine receptor type 2, isoform b | Human | Proteoliposome | PL023 | 10µg, 20µg,100 µg, 200 µg | 42 kDa |
| GPCRs | CCR5 | C-C chemokine receptor type 5 | Human | Proteoliposome | PL024 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 40 kDa |
| GPCRs | CXCR4 | C-X-C chemokine receptor type 4 | Human | Proteoliposome | PL016 | 10 µg, 50 µg, 100 µg | 43 kDa |
| GPCRs | CXCR4-Detergent | C-X-C chemokine receptor type 4 | Human | Detergent | D016 | 25µg ,100 µg ,500 µg,bulk | 40 kDa |
| GPCRs | GLP1R | Glucagon-like peptide 1 receptor | Human | Proteoliposome | PL067 | 10 µg, 50 µg, 100 µg | 55.5 kDa |
| GPCRs | GPR50 | G-protein coupled receptor 50 | Human | Proteoliposome | PL095 | 10 µg, 50 µg, 100 µg | 67.4 kDa |
| GPCRs | GPR54 | G-protein coupled receptor 54 | Human | Proteoliposome | PL097 | 10 µg, 50 µg ,100 µg | 45.2 kDa |
| GPCRs | HMOP | Mu-type opioid receptor | Human | Proteoliposome | PL025 | - | - |
| GPCRs | MT1 | Melatonin receptor | Human | Proteoliposome | PL028 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 40 kDa |
| GPCRs | RXFP1 | Relaxin receptor 1 | Human | Proteoliposome | PL068 | 10 µg, 50 µg ,100 µg | 89.1 kDa |
| Ion Channels | kir1.1b | ATP-sensitive inward rectifier potassium channel 1 isoform b | Mouse | Proteoliposome | PL031 | 10µg, 20µg,100 µg, 200 µg, 500 µg, bulk | 42.7 kDa |
| Ion Channels | kv1.2 | Potassium voltage-gated channel subfamily A, member 2 | Rat | Proteoliposome | PL037 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 57 kDa |
| Ion Channels | kv1.3 | Potassium voltage-gated channel subfamily A, member 3 | Mouse | Proteoliposome | PL036 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 58 kDa |
| Ion Channels | VDAC1 | Voltage-Dependent Anion Channel 1 | Human | Proteoliposome | PL029 | 10 µg, 50 µg ,100 µg | 30.7kDa |
| Ion Channels | VDAC1 – Detergent | Voltage-Dependent Anion Channel 1 | Human | Detergent | D029 | 10 µg, 50 µg, 100 µg | 30.7kDa |
| Ligands | SDF1a | Stromal cell-derived factor 1 | Human | Soluble | S069 | 10 µg, 50 µg ,100 µg | 10.7 kDa |
| Porins | OEP24 | Outer envelope pore protein 24, chloroplastic | Plant | Proteoliposome | PL040 | 10 µg, 50 µg ,100 µg | 24 kDa |
| Porins | OprF | Outer membrane porin F | Bacteria | Proteoliposome | PL045 | 10 µg, 50 µg, 100 µg | 40 kDa |
| Enzymes | gp91phox (Nox2 subunit) | gp91phox | Human | Proteoliposome | PL008 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 55 kDa |
| Enzymes | KMO | Kynurenine 3-monooxygenase | Human | Proteoliposome | PL005 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 55,8 kDa |
| Enzymes | Nox2, p22 Phox | Cytochrome b-245 light chain | Human | Proteoliposome | PL039 | 10 µg, 50 µg ,100 µg | 23,5 kDa |
| Enzymes | Nox4 | Nox4 | Human | Proteoliposome | PL059 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 67 kDa |
| Enzymes | PORCN | Protein-Cysteine N-palmitoyltransferase porcupine | Human | Proteoliposome | PL006 | 10 µg, 50 µg, 100 µg | 55.5 kDa |
| Enzymes | TF | Tissue factor | Human | Proteoliposome | PL053 | 10µg, 20µg ,50µg, 100 µg , 200µg, 500 µg,bulk | 33 kDa |
| Enzymes | T7 RNA Pol | T7 RNA Polymerase | Bacteriophage T7 | Soluble | S192 | 10 µg, 50 µg, 100µg | 100.1 kDa |
| Enzymes | DsbC | Disulfide bond isomerase | E.coli | Soluble | S197 | customized quantity on request. | 25.4 kDa |
| Receptors | CLDN 18.2 | Claudin 18.2 Protein | Human | Proteoliposome | PL119 | 10 µg, 50 µg, 100 µg | 30 kDa |
| Transcriptional regulators | AROS | Active regulator of SIRT1 | Human | Proteoliposome | S052 | 10µg, 20µg ,100 µg , 200 µg, 500 µg,bulk | 15,4 kDa |
| Transporters | Bak | Bcl-2 homologous antagonist killer | Human | Proteoliposome | PL038 | 25µg ,100 µg ,500 µg,bulk | 17 kDa |
| Transporters | EspH | Cytoskeleton-modulating effector of enterohaemorrhagic and enteropathogenic Escherichia coli | Bacteria | Proteoliposome | PL051 | 10 µg, 50 µg, 100 µg | 21.9 kDa |
| Transporters | HCV p7 | Hepatitis C virus P7 | Virus | Proteoliposome | PL042 | 25µg ,100 µg ,500 µg,bulk | 7 kDa |
| Transporters | NhaA | Na(+)/H(+) antiporter NhaA | E. coli | Proteoliposome | PL032 | 10 µg, 50 µg, 100 µg | 43.9 kDa |
| Transporters | UCP1 | Mitochondrial brown fat uncoupling protein 1 | Mitochondria | Proteoliposome | PL047 | 10 µg, 50 µg, 100 µg | 35.1 kDa |
SignalChem公司提供人类重组蛋白，用于研究细胞信号传导的生物技术领域。生产供应高活性激酶、磷酸酶、磷酸二酯酶、组蛋白脱乙酰酶、沉默信息素和参与信号转导的其他细胞蛋白、抗体、肽底物等。包括定制蛋白质开发和化合物分析。
SignalChem is a biotechnology company focused on the research, development and production of innovative cell signaling products. Our company focuses on producing highly purified biologically-active human recombinant proteins. SignalChem strives to support life scientists in academia and biotech by creating effective research tools to advance basic life sciences research and drug discovery efforts.
SignalChem公司的主要产品包括：
Active Enzymes
Antibodies
Biochemical Compounds
Signaling Proteins
Signaling Reagents
Extracellular Ligands
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://fluorochrome.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="SignalChem"> SignalChem地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18995651644
传真：15172469628
邮箱：sales@amyjet.com
0.2916
